• Champalimaud
  • Champalimaud

    The Champalimaud Foundation (CF) is a private, non-profit organisation dedicated to research excellence in biomedical science. Completed in 2010, the Champalimaud Centre for the Unknown (CCU) is a state-of-the-art centre where an unconventional high-risk/high-gain research program (Champalimaud Research –CR), with its three programmes – the Champalimaud Neuroscience Programme (CNP), the Physiology and Cancer Programme (PCP), and the Experimental Clinical Research Programme (ECR), runs in parallel with clinical research in cancer (Champalimaud Clinical Centre – CCC). With an original focus on a systems approach to brain function and behaviour, the CR expanded its organismic research, bringing in molecular and cell biological expertise while ensuring an increased interface between CR and the CCC. CR is organised in 26 research groups (circa 400 researchers) leading independent curiosity-based research programs supported by scientific and technical platforms that combine research and development with high quality services in a plethora of technological areas, and by highly specialised research management and science communication units providing tailored and innovative support. As a result, the CF research community produced a sound scientific record of 723 peer-reviewed original publications (2008-2019; h-index 72; 24,383 summed citations without self-citations) and has been very successful at securing competitive international funding as attested by its 11 active ERC grants.

  • Bruno Costa-Silva, PhD

    Group Leader

    Champalimaud Centre For the Unknown

    Avenida de Brasilia

    1400-038 Lisbon



  • Cancer typesPancreatic, Colorectal, Pulmonary, Ovary Cancer
    Clinical applicationDiagnosis and Follow up of Cancer Disease
    Liquid Biopsy sourcePlasma (EDTA Tubes)
    Technologies available for Liquid BiopsyIsolation and characterisation of Extracellular Vesicles
    Key publicationsMaia, J., Batista, S., Couto, N., Gregório, A.C., Bodo, C., Elzanowska, J., Strano Moraes, M.C., Costa-Silva, B#. Population Analysis of Extracellular Vesicles in Microvolumes of Biofluids. BioRxiv. BioRxiv 2020.01.10.895037, doi:10.1101/2020.01.10.895037 (2020). Under review at the Journal of Extracellular Vesicles. Description of a new method that enables the study of EVs populations in microvolumes of non-purified biofluids, which will be key for the study of protein interactions of EVs in this project.

    Rodrigues, G.; Hoshino, A.; Kenific, C. M.; Matei, I. R.; Steiner, L.; Freitas, D.; Kim, H. S.; Oxley, P. R.; Scandariato, I.; Casanova-Salas, I.; Dai, J.; Badwe, C. R.; Gril, B.; Tesic Mark, M.; Dill, B. D.; Molina, H.; Zhang, H.; Benito-Martin, A.; Bojmar, L.; Ararso, Y.; Offer, K.; LaPlant, Q.; Buehring, W.; Wang, H.; Jiang, X.; Lu, T. M.; Liu, Y.; Sabari, J. K.; Shin, S. J.; Narula, N.; Ginter, P. S.; Rajasekhar, V. K.; Healey, J. H.; Meylan, E.; Costa-Silva, B.; et al., Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nat Cell Biol. 2019 Nov 4. Detailed demonstration on how tumor-derived EVs are responsible for the formation of brain niches supportive of brain metastasis. In this work I contributed to the experimental design and discussion of results.design and discussion of results.

    Ferreira, N., Marques, A., Águas, H., Bandarenka, H., Martins, R., Bodo, C., Costa-Silva, B.#*, Fortunato, E*. Label-Free Nanosensing Platform for Breast Cancer Exosome Profiling. ACS Sensors. 2019 Aug 23;4(8):2073-2083. *These authors share the corresponting authorship. Description of a new method, based on Raman spectroscopy that enables the fast distinction between EVs from healthy or cancerous breast epithelium.

    Zheng, J., Hernandez, J. M., Doussot, A., Bojmar, L., Zambirinis, C. P., Costa-Silva, B., et al. Extracellular matrix proteins and carcinoembryonic antigen-related cell adhesion molecules characterize pancreatic duct fluid exosomes in patients with pancreatic cancer. HPB (Oxford) 20, 597-604, doi:10.1016/j.hpb.2017.12.010 (2018). I contributed to the experimental design of a strategy that uses pancreatic fluid as a source of pancreatic cancer biomarkers in EVs.

    Hoshino, A.*, Costa-Silva, B.*, Shen, T. L.*, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015 Nov 19;527(7578):329-35. Here we define for the first time of the biological basis of the patterns of tumor exosomes distribution throughout the organism and how it dictates tumor metastatic organotropism.
  • CSEM
  • CSEM

    CSEM is a groundbreaking innovation hub for precision microtechnologies and digitalization. Our mission is to develop and transfer world-class technologies to the industrial sector. As a bridge and catalyst for the transfer of technology and know-how between science and economy, we continually adapt our research focus to meet industry’s needs. This constant re-adaptation has taken our center, which was founded in 1984, beyond our historic ties with watchmaking. Today, with 500+ employees and 5 sites in Switzerland, we supply a broad range of markets, including medical, life sciences, automotive, machine tools and space exploration, with an even broader range of technological solutions. To enable liquid biopsy applications in the clinic, we support our biological, clinical and industrial partners along the whole value chain with tailor-made solutions, which range from functionalized precision membranes for biological sample preparation to machine learning algorithms for clinical data processing.

    Samantha Paoletti, PhD

    Research & Business Dev. Manager

    Bahnhofstrasse 1

    7302 Landquart



    Marc Zinggeler, PhD

    R&D Engineer / Project Leader

    Tramstrasse 99

    4132 Muttenz



  • Cancer typesNo restrictions
    Clinical applicationNo restrictions
    Liquid Biobsy SourceNo restrictions
    Technologies available for liquid biopsy-Surface coating and functionalization
    -High-precision membranes and substrates
    -Microfluidics and fluidic handling
    -Automatization and robotics
    -Optical and electrochemical sensing
    -Exosome isolation and fractionation
    -Microphysiological systems for disease modeling
    -Machine learning
    Key publicationsF. Kurth, E. Györvary, S. Heub, D. Ledroit, S. Paoletti, K. Renggli, V. Revol, M. Verhulsel, G. Weder, F. Loizeau, Chapter 3 - Organs-on-a-chip engineering, Organ-on-a-chip, academic Press 2020: 47-130

    M. Zinggeler, T. Brandstetter, J. Rühe, Biophysical Insights on the Enrichment of Cancer Cells from Whole Blood by (Affinity) Filtration. Sci Rep 2019; 9: 1246.

    M. Zinggeler, A. Luu-Dinh, C. Schneider, A. Lücke, D. Schlup, T. Offermans, G. Basset, I. Zhurminsky, S. Fricke, Development of Scalable Fabrication Methods for High-precision Membranes, CSEM Scientific and Technical Report 2019: 52

    S. F. Graf, S. Berchtold, T. Volden, V. Revol, Automated, Disposable Sample Preparation Cartridge for Complementary Diagnostics, CSEM Scientific and Technical Report 2019: 54

    S. Heub, G. Voirin, R. Pugin, M. Despont, T. Bauert, A. Tzannis, G. Weder, Disposable Glass Microfluidics for Nucleic Acids Bioassays, CSEM Scientific and Technical Report 2019: 56
  • Erasmus MC
  • Erasmus MC

    The department of Medical Oncology is one of the departments of the Erasmus MC, the largest university medical center in the Netherlands with more than 14,000 employees. Within the Erasmus MC, the department is part of the Erasmus MC Cancer Institute in which all departments involved in cancer care, education and/or research work together. In addition to providing care to patients with solid malignancies and training of oncology students and residents, the department of medical oncology focuses strongly on clinical and translational research. Researchers from the department have had coordinating roles in studies impacting the world-wide clinical treatment standards in several tumor types including testicular cancer, prostate cancer, bladder cancer, soft tissue sarcomas, and esophageal cancer. Apart from the more than 150 ongoing clinical studies, both pharma- and investigator-initiated, one of the research areas of interest of the department is the development and testing of minimally invasive techniques to capture the molecular characteristics of tumor cells important for treatment decision making. Studies have been done on the robustness of different technologies for liquid biopsies and numerous studies have been done to assess the clinical value of liquid biopsies including in total more than 3,500 patients.

  • Prof. dr. Stefan Sleijfer, MD, PhD

    Medical Oncologist and Head of Department Medical Oncology

    Dr. Molewaterplein 40
    3015 GD Rotterdam Netherlands


    Prof. dr. John Martens, PhD

    Head of lab Translational Cancer Genomics and Proteomics, Department of Medical Oncology

    Dr. Molewaterplein 40
    3015 GD Rotterdam Netherlands


    Dr. Jaco Kraan, PhD

    Lab Translational Cancer Genomics and Proteomics, Department of Medical Oncology

    Dr. Molewaterplein 40
    3015 GD Rotterdam Netherlands


  • Cancer typesBreast cancer, prostate cancer, colorectal cancer, bladder cancer, melanoma
    Clinical applicationPrognostic and predictive value of liquid biopsies, value as early marker of response.
    Liquid Biobsy SourceBlood, plasma, liquor
    Technologies available for liquid biopsyCellSearch, Cytotrack, VyCAP, several NGS platforms
    BiobankSolid tumors (plasma)
    Key publicationsPriestley P, Baber J, Lolkema MP, Steeghs N, de Bruijn E, Shale C, Duyvesteyn K, Haidari S, van Hoeck A, Onstenk W, Roepman P, Voda M, Bloemendal HJ, Tjan-Heijnen VCG, van Herpen CML, Labots M, Witteveen PO, Smit EF, Sleijfer S, Voest EE, Cuppen E. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature. 2019 Nov; 575(7781):210-216. doi: 10.1038/s41586-019-1689-y

    Angus L, Smid M, Wilting SM, van Riet J, Van Hoeck A, Nguyen L, Nik-Zainal S, Steenbruggen TG, Tjan-Heijnen VCG, Labots M, van Riel JMGH, Bloemendal HJ, Steeghs N, Lolkema MP, Voest EE, van de Werken HJG, Jager A, Cuppen E, Sleijfer S, Martens JWM. The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. Nat Genet. 2019 Oct;51(10):1450-1458. doi: 10.1038/s41588-019-0507-7

    Onstenk W, Sieuwerts AM, Kraan J, Van M, Nieuweboer AJ, Mathijssen RH, Hamberg P, Meulenbeld HJ, De Laere B, Dirix LY, van Soest RJ, Lolkema MP, Martens JW, van Weerden WM, Jenster GW, Foekens JA, de Wit R, Sleijfer S. Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells. Eur Urol. 2015 Dec;68(6):939-45. doi: 10.1016/j.eururo.2015.07.007

    van Dessel LF, Beije N, Helmijr JC, Vitale SR, Kraan J, Look MP, de Wit R, Sleijfer S, Jansen MP, Martens JW, Lolkema MP. Application of circulating tumor DNA in prospective clinical oncology trials - standardization of preanalytical conditions. Mol Oncol. 2017 Mar;11(3):295-304. doi: 10.1002/1878-0261.12037

    Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, Martens JW, Gratama JW, Sleijfer S, Foekens JA Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. .J Natl Cancer Inst. 2009 Jan 7;101(1):61-6. doi: 10.1093/jnci/djn419
  • Hahn-Schickard
  • Hahn-Schickard

    Lab-on-a-chip – from the initial idea to the final product. Hahn-Schickard stands for client- and industry-oriented, application-driven research, development, and production with microsystems. With a total of 250 employees at three sites in the Southwest of Germany, we develop innovative products and technologies in research fields with a strong future impact such as healthcare, internet of things, information and communication technologies, sustainable mobility, as well as environmental and natural resources. At the site in Freiburg, the R+D service provider focusses on automation solutions for diagnostics. Fields of research are the automation of Liquid Biopsy workflows and sample preparation for next generation sequencing. With an in-house pilot line, Hahn-Schickard is able to support the product visions of its customers effectively – from the design stage to serial production.

    Dr. Tobias Hutzenlaub

    Group leader Microfluidic Platforms

    Georges-Koehler-Allee 103

    79110 Freiburg



    Peter Jülg

    Group leader Microfluidic Platforms

    Georges-Koehler-Allee 103

    79110 Freiburg



  • Cancer typesColorectal cancer, melanoma, acute lymphoblastic leukemia
    Clinical applicationMonitoring of therapy response, early detection of relapse
    Liquid Biopsy sourceblood, bone marrow
    Technologies available for Liquid BiopsyCentrifugal microfluidic platform consisting of processing device (ready for certification in 2020) and application specific microfluidic chips for ctDNA extraction, qPCR, dPCR and sample preparation for next generation sequencing.
    Key publicationsO. Strohmeier, M. Keller, F. Schwemmer, S. Zehnle, D. Mark, F. von Stetten, R. Zengerle and N. Paust, Centrifugal microfluidic platforms: advanced unit operations and applications, Chem. Soc. Rev., 2015, 44, 6187

    P. Juelg, M. Specht, E. Kipf, M. Lehnert, C. Eckert, M. Keller, T. Hutzenlaub, F. von Stetten, R. Zengerle and N. Paust, Automated serial dilutions for high-dynamic-range assays enabled by fill-level-coupled valving in centrifugal microfluidics, Lab Chip, 2019, 19, 2205

    J.F. Hess, T.A. Kohl, M. Kotrová, K Rönsch, T. Paprotka, V. Mohr, T. Hutzenlaub, M. Brüggemann, R. Zengerle, S. Niemann, N. Paust, Library preparation for next generation sequencing: A review of automation strategies, Biotechnology Advances 2020, in press

    J. Friedrich Hess, M. Kotrová, S. Calabrese, T. Hutzenlaub, R. Zengerle, M. Brueggemann, N. Paust, Automation of amplicon-based library preparation for next generation sequencing by centrifugal microfluidics, 2020, under review
  • Ipatimup
  • Ipatimup
    ipatimup elbs

    The Institute of Molecular Pathology and Immunology of the University of Porto - Ipatimup – is the leading cancer research institute in Portugal and was established in 1989 under the aegis of the University of Porto. The institute is a founding member of the i3S – Institute for Research and Innovation in Health and of the Porto Comprehensive Cancer Center. The institutes’ objectives are to perform research and graduate training in human pathology, oncobiology and population genetics having as main research fields tumor pathology, population genetics and gene-environment interaction in precancerous and cancerous diseases. The institute is strategically located in a campus with a strong focus of Health, next to the largest hospital in the Region and the Oncology Institute of Porto (IPO) as well as the Faculty of Medicine potentiating the scientific knowledge as a means of delivering innovative clinical and translational research in cancer. The institute has state of the art facilities, including a Proteomic core facility, a Genomic and Bioinformatic core facility, advanced microscopy facility, and an animal house with in vivo experimental models. Finally, Ipatimup has an ISO15189 and CAP accredited diagnostic laboratory devoted to molecular and traditional pathology. This laboratory routinely uses next generation sequencing and digital PCR for tumor and liquid biopsy genetic characterization.

  • Prof. Jose Carlos Machado ELBS

    Prof. José Carlos Machado

    Vice- president

    Rua Júlio Amaral de Carvalho,45
    4200-135 Porto


    Prof. Luis Costa

    Prof. José Luis Costa

    Principal investigator

    Rua Júlio Amaral de Carvalho,45
    4200-135 Porto


  • Cancer typesLung cancer, breast cancer, colorectal cancer, pancreatic cancer
    Clinical applicationDetection of primary cancer and relapse, therapy monitoring, identification of biomarkers and resistance mechanisms
    Liquid Biobsy SourceBlood, plasma
    Technologies available for liquid biopsyNext generation sequencing, molecular barcode NGS, digital PCR, Nanoparticle Tracking Analysis (NTA)
    Biobanksolid tumors, blood, plasma, urine
    Key publicationsJoana Fernandes Marques, Susana Junqueira-Neto, Jorge Pinheiro, Jose Carlos Machado and Jose Luis Costa (2020) Induction of apoptosis increases sensitivity to detect cancer mutations in plasma. European Journal of Cancer (in press).

    Gil Pinheiro, Tania Pereira, Catarina Dias, Claudia Freitas, Venceslau Hespanhol, Jose Luis Costa, Antonio Cunha, and Helder P. Oliveira (2020) Identifying relationships between imaging phenotypes and lung cancer-related mutation status: EGFR and KRAS. Scientific Reports (in press).

    Gabriela Fernandes, Maria Jacob, Natalia Martins, Jose Carlos Machado, Venceslau Hespanhol and Jose Luis Costa (2019) Targeted gene next-generation sequencing panel in patients with advanced lung adenocarcinoma: Paving the way for clinical implementation. Cancers 11 (9).

    Joana Fernandes Marques, Joana Pereira Reis, Gabriela Fernandes, Venceslau Hespanhol, Jose Carlos Machado and Jose Luis Costa (2019) Circulating Tumor DNA: A Step into the Future of Cancer Management. Acta Cytologica 63 (6), 456-465.

    Susana Junqueira-Neto, Ines Batista, Jose Luis Costa and Sonia Melo (2019) Liquid Biopsy beyond Circulating Tumor Cells and Cell-Free DNA. Acta Cytologica 63 (6), 479-488.
  • IRCCS Regina Elena Cancer Research Institute
  • IRCCS Regina Elena Cancer Research Institute

    The Regina Elena Institute (IRE) is one of the two twin Institutes forming Istituti Fisioterapici Ospitalieri (IFO). Founded in 1934, IRE is possibly the oldest Cancer Research Institute in Europe. It includes research laboratories, clinical research services and hospital assistance staffed with >1000 units of personnel. IRE is a member of the ‘Union International Contre le Cancer’ (U.I.C.C.), of the European Organization of Cancer Institutes (O.E.C.I.), of the European Organization for Research and Treatment of Cancer (E.O.R.T.C. - Early ClinicaI Trial Group), and is referral center of the World Health Organization (WHO). Since 2015 IRE has been accredited as O.E.C.I. Comprehensive Cancer Center. IRE actively investigates mechanisms of neoplastic transformation and progression using transcriptomics, proteomics, molecular diagnosis, predictive oncology, and aims at developing targeted therapeutics. IRE features a fully certified BioBank (BB-IRE) for tissue and liquid biopsy. Since 2016 we perform Liquid Biopsy in the standard of care setting (EGFR, Lung cancer). The research laboratories are organized in a large 2500 square meter open space including central facilities. Pre-clinical and co-clinical (PDx) animal studies are ongoing, including a focus on liquid biopsy. IRE has participated and/or is currently involved in several H2020 EU project on liquid biopsy including ULTRAPLACAD (www.ultraplacad.eu), AiPBAND (www.aipband-itn.eu), and OncNGS (http://oncngs.eu).

    Prof. Gennaro Ciliberto

    Scientific Director

    IRCCS Regina Elena Cancer Research Institute

    Via Elio Chianesi 53

    00144 Rome



    Dr. Patrizio Giacomini

    Principal investigator

    Oncogenomics and Epigenetics

    Via Elio Chianesi 53

    00144 Rome



  • Cancer typesSolid tumors (e.g. lung, breast, Gl-tract, melanoma, bladder, brain tumors, H&N cancer) and hematological malignancies (DLBCL). Rare tumors (sarcoma and thyroid).
    Clinical applicationctDNA to assign target therapy in the context of the Standard of Care (SoC) setting, real-life clinical trials, and the activities of our Molecular Tumor Board (IRE-MTB). ctDNA to reveal actionable resistance to treatment. ctDNA in the peri-surgical period (Colorectal). Circulating fusion transcripts in rare tumors (sarcoma). miRNA signatures for diagnosis and treatment (melanoma, bladder, DLBCL, Colorectal). Liquid Biopsy and Radiogenomics.
    Liquid Biobsy SourcePlasma, Cerebrospinal Fluid (CSF), urine, pleural effusions
    Technologies available for liquid biopsyTargeted and custom NGS panels; miRNome analysis. Thermofisher S5 and IonChef, Illumina MiSeq and NextSeq; nanostring and pyrosequencing equipment; conventional (Cobas z480 Roche) and digital (Thermofisher QuantStudio 3D) PCR (dPCR); Hamilton Robotic Station, DEParray Menarini; Affymetrix Station
    BiobankTissue (BBIRE-T) and body fluids (BBIRE-L) BioBanking; >20.000 and >50.000 samples stored, respectively
    Key publicationsRegazzo G, Terrenato I, Spagnuolo M, Carosi M, Cognetti G, Cicchillitti L, Sperati F, Villani V, Carapella C, Piaggio G, Pelosi A, Rizzo MG.A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas. J Exp Clin Cancer Res 2016 Jul 30;35(1):124. doi: 10.1186/s13046-016-0393-07. 2. Sinibaldi, A., C.

    Sampaoli, N. Danz, P. Munzert, L. Sibilio, F. Sonntag, A. Occhicone, E. Falvo, E. Tremante, P. Giacomini, and F. Michelotti. Detection of soluble ERBB2 in breast cancer cell lysates using a combined label-free/fluorescence platform based on Bloch surface waves. Biosens Bioelectron 2017 92: 125-130.

    Marchesi F, Regazzo G, Palombi F, Terrenato I, Sacconi A, Spagnuolo M, Donzelli S, Marino M, Ercolani C, Di Benedetto A, Blandino G, Ciliberto G, Mengarelli A, Rizzo MG. Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study. J Exp Clin Cancer Res. 2018 May 2;37(1):95. doi: 10.1186/s13046-018-0768-5.

    Allegretti, M., B. Casini, C. Mandoj, S. Benini, L. Alberti, M. Novello, E. Melucci, L. Conti, R. Covello, E. Pescarmona, G. M. Milano, A. Annovazzi, V. Anelli, V. Ferraresi, R. Biagini, and P. Giacomini. Precision diagnostics of Ewing's sarcoma by liquid biopsy: circulating EWS-FLI1 fusion transcripts. Ther Adv Med Oncol 2018 10: 1758835918774337.

    Allegretti, M., G. Cottone, F. Carboni, E. Cotroneo, B. Casini, E. Giordani, C. A. Amoreo, S. Buglioni, M. Diodoro, E. Pescarmona, S. Zazza, O. Federici, M. Zeuli, L. Conti, G. Cigliana, F. Fiorentino, M. Valle, P. Giacomini, and F. Spinella. Cross-sectional analysis of circulating tumor DNA in primary colorectal cancer at surgery and during post-surgery follow-up by liquid biopsy. Journal of Experimental & Clinical Cancer Research 2020 CR 39: 69.
  • Kyushu University Beppu Hospital
  • Kyushu University Beppu Hospital
    Koshi Mimori
    Kyushu University Beppu Hosptial

    Kyushu University Beppu Hospital was established in 1931 as a branch of the main hospital of Kyushu University in Fukuoka, Japan. We have four medical departments, such as surgery, internal medicine, orthopedics and the radiation in Beppu city. In our department, we have five senior surgeons for operations of 200 digestive system cancers and 100 breast cancers per year and are mentors who orchestrate a dozen graduate students as mentee for research works to disclose the bona-fide truth to eradicate cancers.

    In our department of surgery, we organize a lab for basic and translational research work. At first, we are elucidating the cancer evolution to foster the intratumor heterogeneity (ITH) which have attracted increasing attention in the cancer research field because ITH presumably contributes to the therapeutic and diagnostic difficulties of cancer. We applied the recent technological innovation conducting the multiregional sequencing approach, which has been popularly used to understand ITH (Uchi R, PLoS Genet 2016, Saito T. Nat Commun 2018, Yokoyama A., Nature 2019).

    The second, we have been enthusiastically identifying cancer specific transcriptomes, non-coding genes, genomic alterations and epigenomic aberrations in the body fluid as the "liquid biopsy" system for early diagnosis of postoperative recurrence, concealed cancers at subclinical level in primary tumors and prediction of the susceptibility to any treatments.

    Anyway, it is a great honor for us to join the ELBS meeting, I would appreciate it for the chairperson Prof. Pantel and who may concern.

  • Koshi Mimori

    Prof. Koshi Mimori

    4546 Tsurumihara,

    Beppu 874-0838,



    Takkaki Masuda

    Takaaki Masuda


    4546 Tsurumihara

    874-0838 Beppu



  • Cancer typesDigestive system cancers, and breast cancers
    Clinical applicationEarly detection of recurrence and prediction of the susceptibility to treatment
    Liquid Biopsy SourcePlasma, serum from cancer patients
    Technologies available for liquid biopsyTarget re-sequencing, ddPCR
    Key publicationsSugimachi K, Sakimura S, Kuramitsu S, Hirata H, Niida A, Iguchi T, Eguchi H, Masuda T, Morita M, Toh Y, Maehara Y, Suzuki Y, Mimori K. Serial mutational tracking in surgically resected locally advanced colorectal cancer with neoadjuvant chemotherapy. Br J Cancer. 119(4): 419-23. 2018

    Ueda M, Iguchi T, Masuda T, Nakahara Y, Hirata H, Uchi R, Niida A, Momose K, Sakimura S, Chiba K, Eguchi H, Ito S, Sugimachi K, Yamasaki M, Suzuki Y, Miyano S, Doki Y, Mori M, Mimori K. Oncotarget. 7(38): 62280-91. 2016

    Iwaya T, Fukagawa T, Suzuki Y, Takahashi Y, Sawada G, Ishibashi M, Kurashige J, Sudo T, Tanaka F, Shibata K, Endo F, Katagiri H, Ishida K, Kume K, Nishizuka S, Iinuma H, Wakabayashi G, Mori M, Sasako M, Mimori K. Contrasting expression patterns of histone mRNA and microRNA 760 in patients with gastric cancer. Clin Cancer Res. 19(23):6438-49. 2013

    Mimori K, Fukagawa T, Kosaka Y, Kita Y, Ishikawa K, Etoh T, Iinuma H, Sasako M, Mori M. Hematogenous metastasis in gastric cancer requires isolated tumor cells and expression of vascular endothelial growth factor receptor-1. Clin Cancer Res. 14(9):2609-16. 2008.

    Yokobori T, Iinuma H, Shimamura T, Imoto S, Sugimachi K, Ishii H, Iwatsuki M, Ota D, Ohkuma M, Iwaya T, Nishida N, Kogo R, Sudo T, Tanaka F, Shibata K, Toh H, Sato T, Barnard GF, Fukagawa T, Yamamoto S, Nakanishi H, Sasaki S, Miyano S, Watanabe T, Kuwano H, Mimori K, Pantel K, Mori M. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res. 73(7):2059-69. 2013

    The National Institute for Biological Standards and Control (NIBSC, UK) is a centre of the MHRA and a global leader in the characterisation, standardisation and control of biological medicines. NIBSC is the world’s major developer and distributor of World Health Organisation (WHO) International Standards (ISs). WHO ISs are the ‘gold standards’ from which countries and manufacturers can calibrate their own working standards for biological testing. WHO ISs are prepared as a single homogeneous batch of several thousand ampoules, are intended to last many years, are not intended for routine use and act as calibrators of assays and secondary standards to enable the harmonization of the measurement of biological activity through traceability to a single common standard. NIBSC has endorsement from the WHO Expert Committee on Biological Standardization to develop WHO ISs for ctDNA. After the initial focus on the development of WHO ISs for EGFR variants (L858R, exon 19 deletions, and T790M) ctDNA and genomic DNA, NIBSC will expand the portfolio to other biomarkers. ctDNA WHO ISs should ideally be commutable with patients’ samples and allow harmonization of variant percentage, DNA fragment size(s), ctDNA yield, and gene copy numbers. Currently NIBSC is assessing the performance of several matrices with various cell-line derived fragmented DNAs to determine the optimal format for the standards, whilst cross-referencing to patient ctDNA materials and other reference materials already on the market.

    Dr. A. Pia Sanzone

    Group Leader of Non-Invasive Biomarkers and Whole Genome Analysis

    Advanced Therapies Division

    Blanche Lane
    South Mimms
    Potters Bar
    EN6 3QG, U.K.


    Malcolm Hawkins

    Senior Scientist Biotherapeutics Division

    Blanche Lane
    South Mimms
    Potters Bar
    EN6 3QG, U.K.


  • Cancer typesInitial focus on EGFR variants (L858R, exon 19 deletions, and T790M) in ctDNA and genomic DNA.
    Clinical applicationctDNA and genomic DNA WHO International Standards that mimic clinical specimens
    Liquid biopsy sourceCell line derived fragmented DNA
    Technologies available for Liquid BiopsyBulk, Freeze-dried fragmented DNA in plasma, digital PCR, NGS
    PublicationsPoster at “Research & Technology Series: Immuno-oncology meeting 10th-11th October 2019, titled: “Development of the First WHO International Standards for ctDNA”
  • Netherlands Cancer Institute - COIN-Consortium
  • Netherlands Cancer Institute - COIN-Consortium

    The COIN-consortium is a Dutch initiative in which a nation-wide team of multidisciplinary specialists are working together towards a coordinated clinical implementation of liquid biopsy ctDNA analysis as an innovative form of minimal invasive molecular diagnostics in the healthcare system of The Netherlands.

    Over the past years multiple platforms have been developed to detect ctDNA, yielding industry-proven technologies suited for clinical implementation (see roadmap), yet, ctDNA clinical utility remains to be proven. The COIN-project aims to enable coordinated implementation of ctDNA diagnostics in clinical practice. The project consists of two parts. Part 1 aims to establish a generic multidisciplinary framework to guide successful clinical implementation of ctDNA and other future biomarkers. Challenges in (pre-)analysis, reporting, quality assurance, cost-effectiveness, clinical utility, and reimbursement will be addressed making use of the knowledge generated in multiple observational studies. These studies focus on colorectal and non-small cell lung cancer as there is a substantial and active ctDNA research community for these two tumor types. Part 2 of COIN is the first Dutch ctDNA biomarker-driven intervention study, MEDOCC-CrEATE, in which patients with stage II colon cancer will be offered adjuvant chemotherapy based on the presence of ctDNA in their blood after surgery. The intervention arm will be compared to current standard of care. The patient inclusion of MEDOCC-CrEATE started in June 2020.

    Contact: COIN@nki.nl

  • Daan van den Broek, PhD

    Head Dept of Laboratory Medicine

    The Netherlands Cancer Institute /Antoni van Leeuwenhoek


    Prof. Gerrit Meijer

    Head Research & Innovation Dept of Pathology; Head Division of Diagnostic Translational Oncology

    The Netherlands Cancer Institute /Antoni van Leeuwenhoek


    Veerle Coupé, PhD

    Chair Decision Modelling Center

    Amsterdam UMC


    Kim Monkhorst, PhD


    The Netherlands Cancer Institute /Antoni van Leeuwenhoek


  • Cancer typesColorectal cancer and non-small cell lung cancer
    Clinical applicationDetection of minimal residual disease, treatment response prediction and monitoring, detection of treatment resistant mechanisms
    Liquid Biobsy SourceBlood, plasma
    Technologies available for liquid biopsy(multiple) PCR-based and NGS-based ctDNA technologies
    Biobankcell-free plasma (ctDNA), white blood cells (germline DNA), solid tumors (tumor DNA)
    Key publicationsSchraa SJ, van Rooijen KL, van der Kruijssen DEW, et al. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study. BMC Cancer. 2020;20(1):790. Published 2020 Aug 20. doi:10.1186/s12885-020-07252-y

    Weber S, Spiegl B, Perakis SO, Ulz CM, Abuja PM, Kashofer K, van der Leest P, Azpurua MA, Tamminga M, Brudzewsky D, Rothwell DG, Mohan S, Sartori A, Lampignano R, Konigshofer Y, Sprenger-Haussels M, Wikman H, Bergheim IR, Kloten V, Schuuring E, Speicher MR, Heitzer E. (2020) Technical evaluation of commercial mutation analysis platforms and reference materials for liquid biopsy profiling. Cancers (Basel) 12, 1588.

    Lampignano R, Neumann MHD, Weber S, Kloten V, Herdean A, Voss T, Groelz D, Babayan A, Tibbesma M, Schlumpberger M, Chemi F, Rothwell DG, Wikman H, Galizzi JP, Bergheim IR, Russnes H, Mussolin B, Bonin S, Voigt C, Musa H, Pinzani P, Lianidou E, Brady G, Speicher MR, Pantel K, Betsou F, Schuuring E, Kubista M, Ammerlaan W, Sprenger-Haussels M, Schlange T, Heitzer E. (2020) Multicenter evaluation of circulating cell-free DNA extraction and downstream analyese for the development of standardized (pre)analytical work flows. Clin Chem 1, 149–160.

    van 't Erve I, Greuter MJE, Bolhuis K, Vessies DCL, Leal A, Vink GR, van den Broek D, Velculescu VE, Punt CJA, Meijer GA, Coupé VMH, Fijneman RJA. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer. J Mol Diagn. 2020 Sep 19:S1525-1578(20)30462-1. doi: 10.1016/j.jmoldx.2020.09.002. Online ahead of print. PMID: 32961317

    van den Broek D, Hiltermann TJN, Biesma B, Dinjens WNM, 't Hart NA, Hinrichs JWJ, Leers MPG, Monkhorst K, van Oosterhout M, Scharnhorst V, Schuuring E, Speel EM, van den Heuvel MM, van Schaik RHN, von der Thüsen J, Willems SM, de Visser L, Ligtenberg MJL. Implementation of Novel Molecular Biomarkers for Non-small Cell Lung Cancer in the Netherlands: How to Deal with Increasing Complexity. Front Oncol. 2020 Jan 22;9:1521. doi: 10.3389/fonc.2019.01521. eCollection 2019. PMID: 32039011
  • Pasteur Hospital
  • Pasteur Hospital

    The Laboratory of Clinical and Experimental Pathology (LPCE) (Pasteur Hospital, University Côte d’Azur) founded in 2006 has an expertise mainly in lung and thyroid cancers and in melanoma. This laboratory developed pathology and biology diagnosis using different approaches (pathological and cytological diagnosis, immunohistochemistry, in situ hybridization and molecular biology using targeted or next generation sequencing). This laboratory is associated with the FHU OncoAge (www.oncoage.org) and the Institute for Ageing and Cancer of Nice (IRCAN, www.ircan.org). Moreover, a dedicated biobank has been set up in the LPCE (www.biobank-cotedazur) mainly focus on blood and tissue samples provided by patients with lung cancer, melanoma and thyroid diseases. A specific training program in biobanking has been created in 2016 (MSc Biobanks and Complex data Management, http://web.univ-cotedazur.fr//en/education/informations-utiles/les-informations-utiles/biobanks-complex-data). A liquid biopsy unit has been developed at the LPCE in 2009 in order to organize translational research programs which have been granted by the French NCI. Moreover, the liquid biopsy unit takes responsability for the detection of different predictive biomarkers in daily practice (EGFR mutations, ALK rearangement, BRAF/NRAS mutations, etc.) and participates to different clinical trials using both specific based PCR sequencing and next generation sequencing approaches with gene panels of different sizes.

    Prof. Paul Hofman, MD, PhD

    Head of the Laboratory of Clinical and Experimental Pathology

    BP 69, Nice



    Prof Marius Ilié, MD, PhD

    Deputy Director, Laboratory of Clinical and Experimental Pathology

    BP 69, Nice



    Dr Véronique Hofman, MD, PhD

    Head of the CTC programs at the LPCE

    BP 69, Nice



  • Cancer typesLung cancer, melanoma (skin and ocular melanoma) & thyroid cancer
    Clinical applicationEarly detection of lung cancer
    Detection of predictive biomarkers
    Identification of resistance mechanisms
    Liquid Biobsy SourceWhole blood, plasma, sera, PBMCs, urines, saliva
    Technologies available for liquid biopsyCTC: CellSearch, ISET, Vortex,
    cfDNA: NGS S5, Genereader, COBAS, IDYLLA
    Biobankwww.biobank-cotedazur.fr : Lung and thyroid cancers and melanoma (tissue and liquid samples)
    Key publicationsMarquette CH, Boutros J, Benzaquen J, Ferreira M, Pastre J, Pison C, Padovani B, Bettayeb F, Fallet V, Guibert N, Basille D, Ilie M, Hofman V, Hofman P; AIR project Study Group. Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study. Lancet Respir Med. 2020 Jul;8(7):709-716.

    Heeke S, Hofman V, Ilié M, Allegra M, Lespinet V, Bordone O, Benzaquen J, Boutros J, Poudenx M, Lalvée S, Tanga V, Salacroup C, Bonnetaud C, Marquette CH, Hofman P. Prospective evaluation of NGS-based liquid biopsy in untreated late stage non-squamous lung carcinoma in a single institution. J Transl Med. 2020 Feb 17;18(1):87.

    Hofman P, Heeke S, Alix-Panabières C, Pantel K. Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients? Ann Oncol. 2019 Sep 1;30(9):1448-1459.

    Calabrese F, Lunardi F, Pezzuto F, Fortarezza F, Vuljan SE, Marquette C, Hofman P. Are There New Biomarkers in Tissue and Liquid Biopsies for the Early Detection of Non-Small Cell Lung Cancer? J Clin Med. 2019 Mar 26;8(3):414.

    Ilié M, Szafer-Glusman E, Hofman V, Chamorey E, Lalvée S, Selva E, Leroy S, Marquette CH, Kowanetz M, Hedge P, Punnoose E, Hofman P. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. Ann Oncol. 2018 Jan 1;29(1):193-199.
  • Stavanger University Hospital
  • Stavanger University Hospital

    Stavanger University Hospital is the only hospital in the large area of south Rogaland on the west coast of Norway. The hospital covers a population of approximately 460.000 inhabitants; the hospital has 785 beds and nearly 8000 employees. Research is one of the main four tasks of the hospital, and cancer is one of the major diagnoses treated.

    The main research areas at the Department of Hematology and Oncology are translational research, clinical trials and development of new treatment strategies. The main focus for the micrometastasis research group at the department is translational research on breast and pancreatic cancer, with a special focus on circulating/disseminated tumor cells and circulating tumor DNA detection. The micrometastasis group has a broad collaboration including both national and international partners, like Karolinska Institutet and the University of Texas M.D. Anderson Cancer Center and was recently acknowledged to be part of The Norwegian Cancer Society’s national expert group on pancreatic cancer. Our micrometastasis research group is located in the Laboratory for molecular biology, a modern multi-disciplinary core facility for cancer research, founded in 2007, with state-of-the art infrastructure and instruments that facilitates a wide range of molecular analyses.

    Bjørnar Gilje (MD, PhD)

    Head at Department of Hematology and Oncology

    Gerd-Ragna Bloch Thorsens gate 8,

    4019 Stavanger,



    Oddmund Nordgård (PhD)

    Chief engineer/Professor

    Gerd-Ragna Bloch Thorsens gate 8,

    4019 Stavanger,



    Kjersti Tjensvoll (PhD)

    Chief engineer/Researcher

    Gerd-Ragna Bloch Thorsens gate 8,

    4019 Stavanger,



  • Cancer typesBreast and pancreatic cancer
    Clinical applicationEarly detection of relapse, disease monitoring, monitoring of therapy response
    Liquid Biobsy SourceBlood, plasma, bone marrow
    Technologies available for liquid biopsyNext generation sequencing (Ion Chief, S5, Proton), digital droplet PCR, LightCycler 480, Flow cytometry, Immunofluoresence microscopy with cell picking.
    BiobankLiquid biopsies (DNA/RNA from CTCs, plasma, bone marrow)

    The PACT-ACT biobank contains blood and plasma samples collected from advanced pancreatic cancer patients before initiation of treatment and every months during chemotherapy, as well as bone marrow samples collected before and after treatment start (PI: Bjørnar Gilje).

    The Prospective Breast Cancer Biobank (PBCB), a regional biobank containing blood, urine and plasma/serum samples collected every 6/12 months for 11 years from 1100 patients with early breast cancer. Patients reported outcome measure (PROM) are also collected, yearly (PIs: Gunnar Mellgren and Håvard Søiland)
    Key publicationsTjensvoll K, Nordgård O, Skjæveland M, Oltedal S, Janssen EAM, Gilje B. Detection of disseminated tumor cells in bone marrow predict late recurrences in operable breast cancer patients. BMC Cancer. 2019 Nov 21;19(1):1131

    Lapin M, Oltedal S, Tjensvoll K, Buhl T, Smaaland R, Garresori H, Javle M, Glenjen NI, Abelseth BK, Gilje B, Nordgård O. Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer. Transl Med. 2018 Nov 6;16(1):300

    Nordgård O, Tjensvoll K, Gilje B, Søreide K. Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer. Br J Surg. 2018 Jan;105(2):e110-e120. Review

    Lapin M, Tjensvoll K, Oltedal S, Buhl T, Gilje B, Smaaland R, Nordgård O. MINDEC-An Enhanced Negative Depletion Strategy for Circulating Tumour Cell Enrichment. Sci Rep. 2016 Jul 19;6:28929

    Tjensvoll K, Lapin M, Buhl T, Oltedal S, Steen-Ottosen Berry K, Gilje B, Søreide JA, Javle M, Nordgård O, Smaaland R. Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer. Mol Oncol. 2016 Apr;10(4):635-43
  • Toulouse University Cancer Institute-Oncopole
  • Toulouse University Cancer Institute-Oncopole
    Logo Toulous

    The Oncopole site of Toulouse University Cancer Institute (IUCT-O), together with Cancer Research Center of Toulouse (CRCT), is a Comprehensive Cancer Center member of Organization of European Cancer Institutes (OECI) offering pioneering therapies and technologies. IUCT‑O has three missions, treatment, research (clinical trials, care management and translational research) and teaching, IUCT-located in the heart of a campus grouping together public and private stakeholders involved in the fight against cancer from basic science to clinical trials. The Prospective Biology Unit within the Medical Laboratory of IUCT-O is dedicated to clinical research, innovation and medico-economic evaluation of liquid biopsies in cancers. Together with clinicians and CRCT research teams and the support of CRCT technology cluster (cell imaging, genomic and transcriptomic with single cell analysis …), we take an active part in translational research and clinical trials. Our projects focus on the development of new circulating biological markers for diagnosis, prognosis, longitudinal follow-up of the disease and prediction of therapeutic response, with the molecular analysis of circulating tumor DNA, enrichment and phenotypic characterization of circulating tumor cells, quantification of circulating miRNAs, using innovative technologies such as digital droplet PCR for ctDNA analysis, ISET technology for CTC enrichment or nCounter Analysis System (Nanostring) for miRNA assays.

  • Prof. Gilles

    Prof. Gilles Favre

    Director of the Cancer Research Center of Toulouse

    1 av Irene Joliot-Curie

    31059 Toulouse cedex 9




    Anne Pradines, PhD

    Prospective Biology Unit leader

    1 av Irene Joliot-Curie

    31059 Toulouse cedex 9



  • Cancer typesSolid tumors (lung, melanoma, breast, ovarian cancer, prostate)
    Clinical applicationEarly detection of primary cancer and relapse, monitoring of therapy response, identification of therapy targets and resistance mechanisms
    Liquid Biobsy SourceBlood, plasma
    Technologies available for liquid biopsyddPCR, Target re-sequencing
    BiobankPlasma, PBMC
    Key publicationsGuibert N, Pradines A, Favre G, Mazieres J. Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages. Eur Respir Rev. 2020;29(155):190052.

    Guibert N, Jones G, Beeler JF, et al. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer. Lung Cancer. 2019;137:1–6

    Keller L, Guibet N, Delaunay M, Casanova A, Farella M, Brayer S, Gilhodes J, Martin E, Favre G, Pradines A, Meyer N. Early ctDNA variation predicts tumor response in melanoma patients treated with immunotherapy. Acta Dermato 2019 ; 99: 206–210.

    Guibert N, Delaunay M, Lusque A, et al. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab. Lung Cancer. 2018;120:108–112.

    Guibert N, Pradines A, Farella M, Casanova A, Gouin S, Keller L, Favre G, Mazieres J. Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS-mutated lung adenocarcinoma. Lung Cancer 2016; 100: 1-4.
  • University Hospital Essen
  • University Hospital Essen

    The laboratories at the Department of Dermatology at the University Hospital Essen are primarily focused on the diagnosis and therapy of skin tumors with the goal of transferring research results directly into the clinic. The main research focus is on malignant melanoma, a malignant tumor that originates from pigment producing cells of the skin called melanocytes. Melanoma is an aggressive tumor with dramatically reduced patient survival when disseminated to distant organs. Despite the historic success of modern cancer drugs, the cure of patients is hampered by the dramatic tumor heterogeneity and plasticity of melanoma leading to therapy failure in most cases and limited diagnostic options to monitor therapy response/resistance over time. The Tumor Heterogeneity and Plasticity lab (headed by Prof. Dr. med. Alexander Roesch) has dedicated reasearch projects towards finding ways to overcome the intrinsic therapy resistance of melanoma cell subpopulations in vitro and in vivo. Specifically, the lab focuses on the characterization of tumor heterogeneity, phenotypic plasticity of melanoma cell subpopulations, bioenergetic metabolism, and histone 3 K4 demethylases. Translational research questions are concentrated on how to overcome inter- and intra-tumor heterogeneity in patients. Liquid biopsies, comprising of the noninvasive analysis of circulating tumor-derived material in the blood, represent an innovative tool in precision oncology and provide a potential way to overcome current limitations associated with tissue biopsies.

    For further details feel free to visit our department’s website and follow our group on Twitter (@LabRoesch).

    Prof. Dr. med. Alexander Roesch

    Group leader of Tumor Heterogeneity and Plasticity

    Hufelandstrasse 55

    45147 Essen, Germany


    Dr.rer.nat. Renata Varaljai

    Postdoctoral scientist

    Hufelandstrasse 55

    45147 Essen, Germany


  • Cancer typesMelanoma
    Clinical applicationMonitoring of therapy response, early detection of relapse and resistance
    Liquid Biobsy SourceBlood, plasma
    Technologies available for liquid biopsyqPCR, digital PCR
    BiobankSCABIO (Skin Cancer Biobank)
    Key publicationsLiquid Biopsy

    Renáta Váraljai, Salma Elouali, Smiths S. Lueong, Kilian Wistuba-Hamprecht, Teofila Seremet, Jens T. Siveke, Jürgen. C. Becker, Antje Sucker, Annette Paschen, Peter A. Horn, Bart Neyns, Benjamin Weide, Dirk Schadendorf, Alexander Roesch: The predictive and prognostic significance of cell-free DNA concentration in melanoma. JEADV, DOI: 10.1111/jdv.16766 (2020)

    Martin Metzenmacher, Renáta Váraljai, Balazs Hegedüs, Igor Cima, Jan Forster, Alexander Schramm, Björn Scheffler, Peter Horn, Christoph Klein, Tibor Szarvas, Henning Reis, Nicola Bielefeld, Alexander Roesch, Clemens Aigner, Volker Kunzmann, Marcel Wiesweg, Jens Siveke, Martin Schuler, Smiths Lueong: Plasma next generation sequencing and droplet digital-qPCR-based quantification of circulating cell-free RNA for non-invasive early detection of cancer. Cancers, 02/2020; 12(2), 353, DOI: 10.3390/cancers12020353 (2020)

    Renáta Váraljai, Kilian Wistuba-Hamprecht, Teofila Seremet, Joey Mark S. Diaz, Jérémie Nsengimana, Antje Sucker, Jan-Malte Placke, Peter A. Horn, Nils von Neuhoff, Batool Shannan, Heike Chauvistré, Felix C. E. Vogel, Susanne Horn, Jürgen C. Becker, Julia Newton-Bishop, Andreas Stang, Bart Neyns, Benjamin Weide, Dirk Schadendorf, Alexander Roesch: Application of circulating cell-free tumor DNA profiles for therapeutic monitoring and outcome prediction in genetically heterogeneous metastatic melanoma. JCO Precision Oncology, DOI: 10.1200/PO.18.00229 (2019)

    Other translational projects

    Jan C. Brase, Robert F. H. Walter, Alexander Savchenko, Daniel Gusenleitner, James Garrett, Tobias Torsten Schimming, Renáta Váraljai, Deborah Castelletti, Ju-Young Kim, Naveen K Dakappagari, Ken Schultz, Caroline Robert, Georgina V. Long, Dr. Paul D Nathan, Antoni Ribas, Keith T. Flaherty, Boguslawa Karaszewska, Jacob Schachter, Antje Sucker, Kurt W Schmid, Lisa Zimmer, Elisabeth Livingstone, Eduard Gasal, Dirk Schadendorf, Alexander Roesch: Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib. Clin Cancer Res, June 9 2021 DOI: 10.1158/1078-0432.CCR-20-3586

    B. Shannan, J. Matschke, H. Chauvistré, F. Vogel, D. Klein, F. Meier, D. Westphal, J. Bruns, R. Rauschenberg, J. Utikal, A. Forschner, C. Berking, P. Terheyden, E. Dabrowski, R. Gutzmer, D. Rafei-Shamsabadi, F. Meiss, L. Heinzerling l, L. Zimmer, Elisabeth Livingstone, R. Váraljai, A. Hoewner, S. Horn, J. Klode, M. Stuschke, B. Scheffler, A. Marchetto, G. Sannino,T.G.P. Gruenewald, D. Schadendorf, V. Jendrossek, A. Roesch: Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E inhibition in melanoma. Eur J Cancer, 03/2019; Volume 109, Pages 137-153
  • University Medical Center Hamburg-Eppendorf
  • University Medical Center Hamburg-Eppendorf
    Network at UKE
    The Liquid Biopsy Translational Research Network at UKE
    It is part of the Univerity Cancer Center Hamburg (UCCH), one of the top cancer center ("Onkologisches Spitzenzentren")
    Individual projects are funded by highly competitive EU grants (ERC, IMI, ERA-Net Transcan, Marie Curie-Sklodowaska Training network).

    The Liquid Biopsy Translational Research Network at UKE has been established by Klaus Pantel and is part of the University Cancer Center Hamburg (UCCH, Director: Prof. Carsten Bokemeyer), one of the top cancer centers („Onkologische Spitzenzentren“) funded by the German Cancer Aid („Deutsche Krebshilfe“) which also funds a novel post-graduate training center for clinical and translational scientists („Mildred-Scheel Nachwuchszentrum“) at UCCH focusing on cancer cell dissemination/metastasis and liquid biopsy. The network has published more than 300 reports (mostly on clinical studies in patients with various types of solid tumors) and individual projects are funded by highly competitive EU grants (ERC, IMI, ERA-Net TRANSCAN, Marie Curie-Sklodowska Training networks).

  • Prof Klaus Pantel

    Prof. Klaus Pantel

    Chairman of Institut of Tumorbiologie

    Martinistr. 52

    20246 Hamburg



    Natalie Reimers

    Natalie Reimers, PhD

    Project manager

    Martinistr. 52

    20246 Hamburg



  • Cancer typesSolid tumors (e.g., prostate, breast, lung, GI-tract, melanoma, bladder, cervical cancer)
    Clinical applicationEarly detection of primary cancer and relaps (MRD), monitoring of therapy response, identification of therapy targets and resistance mechanisms
    Liquid Biopsy sourceBlood, plasma, bone marrow
    Technologies available for Liquid BiopsyCellSearch; Parsortix; others
    BiobankSolid tumors (CTCs, plasma)
    Key publicationsKeller L, Pantel K. Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nat Rev Cancer 2019;19: 553-67.

    Pantel K, Alix-Panabieres C. Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16: 409-24.

    Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ,...Pierga JY, Pantel K. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. JNCI. 2018.

    Werner S, Brors B, Eick J, Marques E, Pogenberg V, Parret A, Kemming D, Wood AW, Edgren H, Neubauer H, Streichert T, Riethdorf S, Bedi U, Baccelli I, Jucker M, Eils R, Fehm T, Trumpp A, Johnsen SA, Klefstrom J, Wilmanns M, Muller V, Pantel K*, Wikman H*. Suppression of early hematogenous dissemination of human breast cancer cells to bone marrow by retinoic Acid-induced 2. Cancer Discov. 2015;5: 506-19. (*shared senior authorship)

    Muller C, Holtschmidt J, Auer M, Heitzer E, Lamszus K, Schulte A, Matschke J, Langer-Freitag S, Gasch C, Stoupiec M, Mauermann O, Peine S, Glatzel M, Speicher MR, Geigl JB, Westphal M, Pantel K*, Riethdorf S. Hematogenous dissemination of glioblastoma multiforme. Sci Transl Med. 2014;6: 247ra101. (*shared senior authorship)
  • University of Gothenburg
  • University of Gothenburg

    University of Gothenburg is among the largest universities in Northern Europe (approx. 47,000 students and 6,000 employees). With eight faculties, University of Gothenburg is also the most wide-ranging and versatile university in Sweden. University of Gothenburg is an active international university engaged in collaborative projects and partnerships globally. Institute of Biomedicine at Sahlgrenska Academy, the medical faculty at University of Gothenburg, has an extensive involvement in education and research. The research activities are many and diverse, but primarily fall into one of four key areas: Infection and Immunology, Cancer and Stem Cell Biology, Genetics and Molecular Medicine, and Cell and Molecular Biology including Glycobiology. The institute actively strives to create environments for translational research, promoting constellations of pre-clinical and clinical groups with extensive international collaborations.

    Anders Ståhlberg, Associate Professor

    Group Leader and Head of Translational Genomics Platform

    Sahlgrenska Center for Cancer Research

    Medicinaregatan 1F

    413 90 Gothenburg



  • Cancer typesSolid tumors
    Clinical applicationMonitoring of treatment efficacy and early detection of therapy resistance and relapse
    Liquid Biobsy SourceBlood, plasma, urine
    Technologies available for liquid biopsyMethods for cell-free DNA-, RNA- and protein analysis as well as single-cell technologies. Focus on ultrasensitive sequencing, especially SiMSen-Seq.
    BiobankBlood, plasma, urine
    Key publicationsJohansson G, Kaltak M, Rîmniceanu C, Singh AK, Lycke J, Malmeström C, Hühn M, Vaarala O, Cardell S, Ståhlberg A. Ultrasensitive DNA immune repertoire sequencing using unique molecular identifiers. Clinical Chemistry, 2020, 20:hvaa159.

    Andersson D, Fagman H, Dalin M, Ståhlberg A. Circulating cell-free tumor DNA analysis in pediatric cancers. Molecular Aspects of Medicine, 2020, 72:100819.

    Johansson G, Andersson D, Filges S, Li J, Muth A, Godfrey TE, Ståhlberg, A. Considerations and quality controls when analyzing cell-free tumor DNA. Biomolecular Detection and Quantification, 2019, 17:100078.

    Ståhlberg A, Krzyzanowski PM, Egyud M, Filges S, Stein L, Godfrey TE. Simple multiplexed PCR-based barcoding of DNA for ultra-sensitive mutation detection by next-generation sequencing (SiMSen-Seq). Nature Protocols, 2017, 12:664-82.

    Ståhlberg A, Krzyzanowski PM, Jackson JB, Egyud M, Stein L, Godfrey TE. Simple, multiplexed, PCR-based barcoding of DNA enables sensitive mutation detection in liquid biopsies using sequencing. Nucleic Acids Research, 2016, 44:e105
  • University of Patras
  • University of Patras
    uni patras
    uni patras 2

    University of Patras was founded in 1964. It has 3.931 Postgraduate students, 35 Departments, 161 Laboratories and 17 Clinics, The Department of Biology was founded in 1967 and is the first Department of Biology founded in Greece. The Department provides studies on all aspects of Biological science. The research activities of the members of the department cover a wide range of cutting-edge biological technologies. The Department of Biology is housed in a building of 25000 sq.m. and has a significant infrastructure of scientific equipment distributed in educational and research laboratories.

    The Laboratory of Biochemistry/Liquid Biopsy situated in the Department of Biology is focused on the Evaluation of signal transduction pathways in Cancer Cells. Enumeration and Characterization of Circulating and Disseminated Tumor Cells (CTCs/DTCs). Investigation of the crosstalk between CTCs and Immune Cells. Development of innovative diagnostic tools for the detection of circulating tumor cells (CTCs) in patients' blood. Assessment of tailor-made substrates for three-dimensional (3D) cultures of tumor cells and CTCs to test drug efficacy (laser-made 3D scaffolds induced on natural biopolymer films). Participation in the development of hyperspectral artificial vision-guided robotic microscope for fixed cells and live cell imaging (CTCs).

    Galatea Kallergi, Msc, PhD

    Assistant Professor of Biochemistry, Division of Genetics, Cell and Developmental Biology

    Department of Biology
    University of Patras
    26504 Patras


  • Cancer typesBreast Cancer, Colon Cancer, NSCLC, SCLC etc
    Clinical applicationIdentification of new biomarkers and therapeutic targets on CTCs, Exosomes etc. Development of new methods for culturing and imaging CTCs for testing drug efficacy.
    Liquid Biopsy sourceBlood, plasma, Bone marrow
    Technologies available for Liquid BiopsyHigh Resolution Image Analysis systems (ZEISS Axioscope), Transmission Electron Microscope (TEM), Scanning Electron Microscope (SEM), Real Time -PCR etc
    BiobankIsolated CTCs from patients with solid tumors, ISET Filters with CTCs from NSCLC and Breast Cancer patients.
    Key publicationsG. Kallergi, O. Hoffmann, AK. Bittner, L. Papadimitriou, N Zacharopoulou, M. Zervakis, S. Sfakianakis, C. Stournaras, V. Georgoulias, R. Kimmig, S. Kasimir-Bauer. CXCR4 and JUNB double positive disseminated tumor cells are frequently detected in breast cancer patients at primary diagnosis (Under press in Therapeutic Advances in Medical Oncology).

    G. Kallergi, V. Tsintari, S Sfakianakis, E.S. Bei, N. Zacharopoulou, C. Stournaras, M. Zervakis and V. Georgoulias The prognostic value of JUNB-positive CTCs in metastatic breast cancer; from bioinformatics to immunophenotype. Breast Cancer Res. 2019 Aug 1;21(1):86..

    G. Kallergi, D. Aggouraki, N. Zacharopoulou, C. Stournaras, V. Georgoulias, S.S. Martin. Evaluation of microtentacles on Circulating Tumor Cells (CTCs); Interaction between CTCs and blood cells through cytoskeletal proteins. Breast Cancer Res. 2018 Jul 5;20(1):67.

    G, Kallergi, E.K. Vetsika, D. Agouraki, E. Lagoudaki, A. Koutsopoulos, F. Koinis , P. Katsarlinos, M. Trypaki, I. Messaritakis, C. Stournaras, V. Georgoulias, A. Kotsakis. Evaluation of PD-L1/PD-1 on Circulating Tumor Cells (CTCs) in patients with advanced non-small cell lung cancer (NSCLC). Therapeutic Advances in Medical Oncology Journal, 2018 Jan 15;10.

    Agelaki, Melina Dragolia, H. Markonanolaki, S. Alkahtani, Ch. Stournaras, V. Georgoulias, G. Kallergi, Phenotypic characterization of circulating tumor cells (CTCs) in triple negative breast cancer patients (TNBC), Oncotarget 2017 Jan 17;8(3):5309-5322.